TB-500
Also: TB-500, TB500, TB 500, Thymosin Beta-4 fragment, TΒ4 fragment, Thymosin Beta-4 (research designation)
This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more
TB-500 is a synthetic research peptide discussed in the literature in connection with thymosin beta-4 (TΒ4), a naturally occurring actin-binding peptide. It is most often described as corresponding to the actin-binding region of TΒ4, although sources vary on whether "TB-500" denotes the full-length protein or a shorter synthetic fragment, so its exact identity warrants editorial and source verification. The available data come predominantly from preclinical, animal, and in-vitro studies of thymosin beta-4 rather than from controlled human research, and the evidence is limited and requires careful interpretation due to study-design and translation limitations. TB-500 is handled as a research-use-only material and is not an approved therapeutic.
Mechanism as described in the literature
Thymosin beta-4, the parent molecule commonly referenced for TB-500, is described in the research literature as an actin-sequestering peptide: it binds monomeric G-actin and is reported to influence actin polymerization and cytoskeletal dynamics in in-vitro systems. Through these actin-related interactions, TΒ4 has been associated in preclinical and animal models with cellular processes such as cell migration, though the mechanisms attributed specifically to "TB-500" remain incompletely characterized and are largely extrapolated from TΒ4 studies.
Because "TB-500" is a research and commercial designation rather than a standardized pharmacological entity, its reported mechanism depends on how a given source defines the molecule. The relationship between the marketed peptide and full-length TΒ4 — including sequence length and any N-terminal modification — varies between sources and should be confirmed against primary documentation rather than assumed.
Research areas
- Actin binding and cytoskeletal dynamics (in-vitro / mechanistic)
- Cell migration in preclinical and animal models
- Thymosin beta-4 biology in cellular and preclinical model systems
- Angiogenesis-related cellular processes (reported in animal/in-vitro studies)
- Analytical identity and purity characterization (documentation and testing visibility)
Documentation notes
References
Frequently asked questions
What is TB-500?+
TB-500 is a synthetic research peptide discussed in connection with thymosin beta-4, a naturally occurring actin-binding peptide. Sources differ on whether the name refers to the full-length protein or a shorter fragment, so its exact identity should be verified against primary documentation. It is handled as a research-use-only material, not an approved therapeutic.
Is TB-500 the same as thymosin beta-4?+
Not necessarily. The literature and commercial sources use the terms inconsistently — some treat them as equivalent, while others describe TB-500 as a fragment corresponding to the actin-binding domain of TΒ4. This ambiguity is unresolved and requires editorial and source verification.
What does the current evidence show?+
Most available evidence comes from preclinical, animal, and in-vitro studies of thymosin beta-4, focused on actin binding and related cellular processes. Controlled human data are limited, and findings should be interpreted cautiously given study-design and translation limitations. No therapeutic use is established or implied.